Turnstone Biologics scores $41.4 mln Series B
Canada-based Turnstone Biologics Inc, a developer of new oncolytic viral immunotherapies, has closed $41.4 million Series B financing. OrbiMed led the round with participation from F-Prime Capital Partners, FACIT and Versant Ventures.
2 November 2016•1 min read
